| Literature DB >> 35615579 |
Xin Su1, Mingyang Zhou2, Yingjian Li2, Na An3, Fan Yang1, Guoxia Zhang1, Lianjiang Xu4, Hengwen Chen1, Hongjin Wu5, Yanwei Xing1.
Abstract
Ischemic heart disease (IHD) is currently one of the leading causes of death among cardiovascular diseases worldwide. In addition, blood reflow and reperfusion paradoxically also lead to further death of cardiomyocytes and increase the infarct size. Multiple evidences indicated that mitochondrial function and structural disorders were the basic driving force of IHD. We summed up the latest evidence of the basic associations and underlying mechanisms of mitochondrial damage in the event of ischemia/reperfusion (I/R) injury. This review then reviewed natural plant products (NPPs) which have been demonstrated to mitochondria-targeted therapeutic effects during I/R injury and the potential pathways involved. We realized that NPPs mainly maintained the integrality of mitochondria membrane and ameliorated dysfunction, such as improving abnormal mitochondrial calcium handling and inhibiting oxidative stress, so as to protect cardiomyocytes during I/R injury. This information will improve our knowledge of mitochondrial biology and I/R-induced injury's pathogenesis and exhibit that NPPs hold promise for translation into potential therapies that target mitochondria.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35615579 PMCID: PMC9126658 DOI: 10.1155/2022/8726564
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Figure 1Mitochondrial damage in ischemia/reperfusion injury. Cyt c: cytochrome c; TCA: tricarboxylic acid cycle; NADH: nicotinamide adenine dinucleotide; ROS: reactive oxygen species; MMP: mitochondrial membrane potential; ADP: adenosine diphosphate; FADH: flavin adenine dinucleotide; ATP: adenosine triphosphate; mtDNA: mitochondrial DNA; VDAC: voltage-dependent anion channel; MCU: mitochondrial Ca2+ uniporter; K-ATP: adenosine triphosphate-sensitive potassium channel; Cyp D: cyclophilin D. Created with http://BioRender.com.
Detected studies reporting cardioprotective effects of polyphenols against mitochondrial damage in I/R injury.
| Author | NPPs | Source | Experiment | Model | Administration | Dosage | Target | Ref. |
|---|---|---|---|---|---|---|---|---|
| Xing Chang | Quercetin | Ginkgo biloba | H/R | Human cardiomyocytes | Incubate | 50, 100, 150, 200, and 250 mg/L | ROS, MMP, SIRT1/TMBIM6, and MRF | [ |
| Tonghua Li | EGb761 | Ginkgo biloba | H/R | H9c2 cells | Incubate | 100 mg/ml, 2 | MitoBKCa, superoxide | [ |
| Jia Min | Hydroxysafflor yellow A | Carthamus tinctorius L. | H/R | H9c2 cells | Incubate | 1.25, 5, and 20 | MEM, PI3K/Akt/HKII | [ |
| Chenxi Luo | Ferulic acid | Cimicifuga foetida L. | H/R | H9c2 cells | Incubate | 12.5 | MPP, ROS, and PINK1/Parkin | [ |
| Dongmin Yu | Resveratrol | Grape | H/R | NPCMs | Incubate | 1, 2, 4 | PI3K/Akt, ROS | [ |
| Luisa F González Arbelaez | Flavan-3-ols, (-)-epicatechin, and procyanidin B2 | Cocoa | I/R | SHR; Wistar rats | Perfuse | 30 | Ca2+-induced mPTP opening, MMP, and Akt/GSK-3 | [ |
| Katrina Go Yamazaki | (-)-Epicatechin | Cocoa | I/R | SD rats | Intravenous administration | 10, 20 mg/kg | MRR, NADH, MMS, and NOS/sGC | [ |
| Luisa F González Arbelaez | Rutin, caffeine, and chlorogenic acid | Ilex paraguariensis | I/R | Wistar rats | Perfuse | 30 | mPTP opening, Akt/eNOS, and GSH | [ |
| Cheng Zeng | Luteolin-7-O- | Dracocephalum Moldavica L. | I/R | SD rats | Gavage | 3, 10, 30 mg/kg | MMS, PI3K/Akt/GSK-3 | [ |
| Limin Meng | Naringenin | Citrus | I/R | SD rats | Perfuse | 1.25, 2.5, 5, 10, 20, and 40 | ROS, K-ATP | [ |
| Po Yee Chiu | Schisandrin B | Fructus Schisandrae | I/R | SD rats | Gavage | 1.2 mmol/kg | GSH, MEM | [ |
| Po Yee Chiu | Schisandrin B | Fructus Schisandrae | I/R | SD rats | Gavage | 1-2 mmol/kg | Ca2+-induced mPT, and ROS | [ |
| Zhangping Liao | Resveratrol | Grape | I/R | Kun-Ming mice | Gavage | 2 mg/kg | VDAC1, Cyt c, and mPTP opening | [ |
NPPs: natural plant products; I/R: ischemia-reperfusion; SHR: spontaneously hypertensive rats; mPTP: mitochondrial permeability transition pore; MMP: mitochondrial membrane potential; TMBIM6: transmembrane BAX inhibitor-1 motif-containing 6; SIRT1: silent information regulator protein 1; NPCMs: neonatal rat primary cardiomyocytes; MRR: mitochondrial respiration rate; NOS: nitric oxide synthase; sGC: soluble guanylate cyclase; GSK: glycogen synthase kinase; ROS: reactive oxygen species; PI3K: phosphatidylinositol-3-kinase; ERK: extracellular signal-regulated kinase; NADH: nicotinamide adenine dinucleotide; NADPH: nicotinamide adenine dinucleotide phosphate; HR: hypoxia/reoxygenation; MitoBKCa: mitochondrial large-conductance Ca2+-activated K+ channels; GSH: glutathione; MRF: mitochondrial respiratory function; SD: Sprague-Dawley; MMS: myocardial mitochondrial structure; MEM: mitochondrial energy metabolism; K-ATP: adenosine triphosphate-sensitive potassium channel; ERK: extracellular signal-regulated kinase: Cyt c, cytochrome c; PINK1: phosphatase and tensin homolog-induced putative kinase 1; VDAC1: voltage-dependent anion channel 1.
Detected studies reporting cardioprotective effects of saponins against mitochondrial damage in I/R injury.
| Author | NPPs | Source | Experiment | Model | Administration | Dosage | Target | Ref. |
|---|---|---|---|---|---|---|---|---|
| Qianhui Li | Ginsenoside Rg1 | Panax ginseng | H/R | H9c2 cells | Incubate | 10, 20, 40, and 60 | MMP, ROS, and Nrf2/HO-1 | [ |
| Yang Wang | Ginsenoside Rd | Panax ginseng | I/R; H/R | SD rats; NPCMs | Intravenous administration; incubate | 50 mL/kg; 10 | MMP, Akt/GSK-3 | [ |
| Qingxia Huang | Ginsenoside Rc | Panax ginseng | I/R; H/R | Kunming mice; H9c2 cells | Gavage; incubate | 10 mL/kg; 2.5, 5, and 10 | ATP, SIRT1/PGC1 | [ |
| Haijie Yu | Gypenosides | Gynostemma pentaphyllum | I/R | Wistar rats | Gavage | 50, 100, and 200 mL/kg | ROS, ATP, Cyt c, and MRF | [ |
| Min Wang | Calenduloside E | Aralia elata (Miq.) Seem | I/R | SD rats | Gavage | 15 mg/kg | MMP, mPTP opening, and AMPK/OPA1 | [ |
HO-1: heme oxygenase 1; Nrf2: NF-E2-related factor 2; AMPK: AMP-activated protein kinase; OPA1: optic atrophy 1.
Detected studies reporting cardioprotective effects of terpenoids against mitochondrial damage in I/R injury.
| Author | NPPs | Source | Experiment | Model | Administration | Dosage | Target | Ref. |
|---|---|---|---|---|---|---|---|---|
| Rongchuan Yue | Lycopene | Tomato | H/R | NPCMs | Incubate | 5 | ROS, mPTP, Cyt c, and caspase-3 | [ |
| Huaming Cao | Taxol | Taxus | I/R | SD rats | Perfuse | 0.1, 0.3, and 1 | ROS, JNK1/HO-1 | [ |
| Junjie Xiao | Taxol | Taxus | I/R | SD rats | Perfuse | 0.1, 0.3, 1 | ROS, mPTP opening, and Cyt c, Ca2+ | [ |
| Qiang Li | Tanshinone IIA | Salvia miltiorrhiza Bunge | I/R; H/R | SD rats; NPCMs | Intravenous administration; incubate | 10, 20 mg/kg; 1, 10 | ROS, PI3K/Akt/mTOR | [ |
| Jiankai Zhong | Tanshinone IIA | Salvia miltiorrhiza Bunge | I/R; H/R | C57BL/6 mice; CMECs | — | 5, 25 mg/kg; — | MMP, mPTP opening, and SIRT1/PGC1 | [ |
mTOR: mammalian target of rapamycin; CMECs: cardiac microvascular endothelial cells; PGC1α: peroxisome proliferator-activated receptor gamma-coactivator 1α; JNK1: c-Jun N-terminal kinases 1.
Detected studies reporting cardioprotective effects of alkaloids against mitochondrial damage in I/R injury.
| Author | NPPs | Source | Experiment | Model | Administration | Dosage | Target | Ref. |
|---|---|---|---|---|---|---|---|---|
| Shiru Bai | Anisodamine | Anisodus | I/R; H/R | SD rats; NPCMs | Perfuse; incubate | 0.3 mmol/L; 10−6 mmol/L | K-ATP, MMP, MEM, and MMS | [ |
| Tiejun Zhang | Tetrandrine | Stephania tetrandra S Moore | H/R | H9c2 cells | Incubate | 1, 5, 25 mmol/L | MMP, JAK 3/STAT 3/HK II | [ |
| Yongjun Wang | Berberine | Coptis chinensis | I/R | SD rats | Gavage | 200 mg/kg | MMP, Cyt c | [ |
| Young Soo Lee | Higenamine | Aconite | I/R | SD rats | Intraperitoneal administration | 1, 5, and 10 mg/kg | Cyt c, HO-1 | [ |
STAT3: signal transducer and activator of transcription 3; JAK3: Janus kinase 3; HKII: hexokinase II.
Figure 2Cardioprotective effects of natural plant products targeting mitochondria in myocardial ischemia/reperfusion injury. TMBIM6: transmembrane BAX inhibitor-1 motif-containing 6; SIRT1: silent information regulator protein 1; eNOS: endothelial nitric oxide synthase; GSK: glycogen synthase kinase; ERK: extracellular signal-regulated kinase; STAT3: signal transducer and activator of transcription 3; JAK3: Janus kinase 3; mTOR: mammalian target of rapamycin; PGC1α: peroxisome proliferator-activated receptor gamma-coactivator 1α; HO-1: heme oxygenase 1; Nrf2: NF-E2-related factor 2; PINK1: phosphatase and tensin homolog-induced putative kinase 1; JNK1: c-Jun N-terminal kinases 1; AMPK: AMP-activated protein kinase; OPA1: optic atrophy 1. Created with http://BioRender.com.